All In Biotech

Drug Trial Radar · NCT04808648

The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

A Single-center, Open-label, Drug-drug Interaction Study of SH-1028 Tablets in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 6, 2021

Primary completion

Jun 10, 2021

Study completion Jun 30, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I study to assess the drug-drug interaction of SH-1028 tablets and Itraconazole/Rifampicin tablets. The study also evaluates the pharmacokinetic and tolerability of SH-1028 tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.

Conditions

  • Healthy Male Volunteers

Interventions

  • SH-1028Drug

    tablet, oral, 200 mg once daily for day 1 and day 12

  • ItraconazoleDrug

    capsule, oral, 200 mg twice daily for day 8 to day 14

  • RifampicinDrug

    capsule, oral, 600 mg once daily for day 8 to day 16

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose
  2. AUC(0-last)Time frame: Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose
  3. AUC(0-∞)Time frame: Blood samples collected on Day 1 and Day 12 (arm 1)/Day 14 (arm 2) at pre-dose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours post SH-1028 dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital with Bengbu Medical College

    Bengbu, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.